EU Approves New Genomic Techniques (NGT) Rules: What Gene-Edited Plant Developers Need to KnowJune 17, 2026

In today’s dynamic agricultural landscape, a proactive and well-defined regulatory and intellectual property (IP) strategy is a core driver of business growth for biotechnology-based companies. As the seed sector embraces innovations like CRISPR-based genome editing and advanced trait stacking, navigating the complexities of global regulatory oversight is critical. 

Today’s news regarding the European Parliament vote on the new regulation for New Genomic Techniques (NGTs) is positive news for innovators, but it does not mean that the EU will allow gene edited plants to be commercialized immediately, which some news headlines and reports unintentionally imply.

After years of treating every gene-edited plant like a genetically modified organism, the EU is shifting policy to rules that judge a plant by what it actually is rather than by the method used to make it. They’ve been working on this topic since 2023.

The Council formally adopted the new regulation on New Genomic Techniques (NGTs) on April 21, 2026, and on June 17, 2026 the European Parliament gave its final approval, clearing the regulation for publication in the Official Journal.

For anyone building a business around plant gene editing, this regulatory change once implemented will direct which products are more likely to receive EU market authorization quickly, and which ones still face years of review.

Two Tiers: NGT-1 and NGT-2

The regulation bifurcates gene-edited plants into two categories, NGT-1 and NGT-2, which determines their regulatory treatment and legal obligations including route to intellectual property protection.

NGT-1 covers plants that could have arisen naturally or through conventional breeding. These are treated like conventionally bred varieties: no GMO risk assessment, no product labelling beyond the seeds and reproductive material themselves, and no further checks on their offspring. For breeders, this means a far shorter and less expensive route to market authorization. However, plants engineered for herbicide-tolerance or to produce insecticidal substances cannot become NGT-1 plants. This is an important limitation that is often not mentioned or overlooked.

NGT-2 covers plants with more complex changes. These stay under the existing GMO regime, with full risk assessments, authorization, traceability, and labelling.

What to Watch

While overall this is positive, it is still two years away from implantation. Once in force, commercialization hurdles will remain. Each independent member state is a sovereign nation. This is why even though seed companies get EU “EFSA approval” for food/feed use with no safety issues noted, the products are still not permitted in many countries. Therefore, in practice, time will tell whether this will have measurable impact on the actual adoption of gene edited plants within countries that are part of the EU. We will need to wait until the implementation, which is a still a few years away.

The NGT-1 tier will open up opportunities, but key issues remain to be addressed in the EU such as compliance and traceability. Even NGT-1 plants must be registered in a public EU database, and all seed bags and reproductive material must be labelled as NGT-1, to allow farmers to make an informed choice. So in practice, these materials will NOT be treated the same as conventional products.

The EU is a fragmented market and as mentioned, sovereign member states can restrict or ban NGT-2 cultivation on their own territory, so a Europe-wide strategy will continue to mean working around a patchwork of national decisions.

Thankfully, NGTs remain patentable, except for those traits or sequences occurring in nature or produced by biological means. There will also be safeguards to prevent market concentration, and to ensure affordability and fair access for farmers, so they retain the right to save and replant seeds. The regulation relies on transparency rather than the complete patent ban Parliament had once pushed for. Developers will have to declare patents in a public database, and the Commission plans a code of conduct and an expert group on this topic. Expect licensing to get a lot more complicated!

Once the regulations are published in the Official Journal, most of the provisions take effect after a 24-month transition, so the framework should apply from mid-2028.

This leaves a short window to get product development pipelines, IP, and regulatory strategies ready now, before it is enacted. The companies that come out ahead will be the ones designing for precision and sustainability, with clear strategies on event development in light of the the NGT-1/NGT-2 categories.

For startups and established players alike, a deep understanding of the regulatory environment, coupled with a robust global IP strategy, is essential to unlock opportunities, mitigate risks, and secure a competitive edge.

Cassie Edgar is a scientist and a registered patent attorney who represents both startup and publicly traded companies around the world in IP, regulatory, licensing, and corporate law matters. Cassie has extensive experience securing regulatory authorizations for agricultural technologies, protecting IP, and enabling research collaborations. For 14 years, she served as IP Counsel, Sr. Regulatory Counsel, and Director at Pioneer DuPont (now Corteva).